Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed Refractory Multiple Myeloma
Allogeneic Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CART (AlloCAR T) products for cancer, today announced that data from its Phase 1 UNIVERSAL study…
